Specifically, the CURB regimen is suitable for anatomically targeted intervention in oligoprogressive NSCLC, SINDAS provides a potentially curative strategy for EGFR‐positive oligometastatic disease, and the anlotinib combination improves the short‐term efficacy of antiangiogenic agents against SCLC. The gene discussed is EGFR; the disease is small cell lung carcinoma.